Minoru Ueda* and Yasuhiro Seta
Introduction: Amyotrophic Lateral Sclerosis (ALS) is a devasting neuroinflammatory disease of the Central Nerve System (CNS) and current ALS treatments do not result in complete remission leading to death 3-5 years in most cases. Here we report the intriguing case of an ALS patient treated by transnasal and intravenous administration of stem cellconditioned medium and clinical improvement in disease severity and delay of disease progression.
Case Report: In a 68-years-old male patient suffering from muscle weakness and fasciculations, progressive muscular atrophy, a variant of ALS, was diagnosed after extensive examinations ruling out other diseases in April 2019 in Yokohama city hospital and followed by Kitasato university hospital from June 2020, then finally referred to our clinic in January 2021. In our clinic, the patient received transnasal and intravenous administration of the Stem Cell From Human Exfoliated Deciduous Teeth Derived Conditioned Medium (SHEDCM) from September 2021. The success of the therapy was followed by ALS Functional Rating ScoreRevised (ALSFRS-R) and Range Of Motion (ROM). Pulmonary function was monitored by SpO2 continuously in his home and by pulmonary function test in the university hospital. Unexpected improvements occurred one week after starting intravenous therapy with SHEDCM, ROM in limbs and neck expanded remarkably and continued this amelioration for the following 5 months. This ameliorated symptom in ROM confirmed the remission of one of the typical signs of ALS, spasticity contracture. It improved the patient’s quality of life and activities of daily living. During the period in this therapy, we did not experience any adverse effects related to thistherapy. Conclusion: The therapy described here may be a promising approach to treating some kinds of motor neuron disease such as ALS.
